{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:17:38Z","timestamp":1788880658742,"version":"build-2803163510"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n                           <jats:sup>18<\/jats:sup>F-fluorocholine PET\/CT is commonly used for staging and assessing treatment response in prostate cancer patients. Growing clinical experience has shown that <jats:sup>18<\/jats:sup>F-fluorocholine can actually accumulate in sites of inflammation. We report a rare case of a prostate cancer patient with incidentally detected Peyronie disease.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003082","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:30:29Z","timestamp":1590010229000},"page":"575-576","source":"Crossref","is-referenced-by-count":2,"title":["Peyronie Disease as an Example of Nononcological, Inflammatory Uptake of 18F-Fluorocholine in Patient With Prostate Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Paulina","family":"Cegla","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kubiak","sequence":"additional","affiliation":[{"name":"Greater Poland Cancer Registry, Greater Poland Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Witkowska","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Affidea Poznan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Czepczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/21681805.2015.1005665","article-title":"Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography\/computed tomography imaging for the initial staging of patients with intermediate- to high-risk prostate cancer: a retrospective analysis","volume":"49","year":"2015","journal-title":"Scand J Urol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: metaanalysis and critical review of available data","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/01.ju.0000056901.95996.43","article-title":"Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography","volume":"169","year":"2003","journal-title":"J Urol"},{"key":"bib4-20230925","first-page":"84","article-title":"18F-fluorocholine positron emission tomography-computed tomography (18F-FCH PET\/CT) for staging of high-risk prostate cancer patients","volume":"13","year":"2019","journal-title":"Can Urol Assoc J"},{"key":"bib5-20230925","first-page":"142","article-title":"Peyronie\u2019s disease: a review","volume":"5","year":"2003","journal-title":"Rev Urol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"bcr2013201446","DOI":"10.1136\/bcr-2013-201446","article-title":"A malignant differential diagnosis for Peyronie\u2019s disease","volume":"2014","year":"2014","journal-title":"BMJ Case Rep"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00259-009-1329-0","article-title":"Active inflammation in 18F-methylcholine PET\/CT","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MNM.0b013e328330adc5","article-title":"18F-choline PET\/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer","volume":"31","year":"2010","journal-title":"Nucl Med Commun"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nucmedbio.2017.04.004","article-title":"PET\/CT with 18F-choline: physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET\/CT bio-distribution and pitfalls. A southern Italian experience","volume":"51","year":"2017","journal-title":"Nucl Med Biol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:09:46Z","timestamp":1695622186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003082","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}